Schering-Plough Merger Offers Merck OTC Business, Zegerid Switch Rights
This article was originally published in The Tan Sheet
Executive SummaryMerck stands to pick up the switch rights to the proton pump inhibitor Zegerid at the head of a strong switch program if its planned acquisition of Schering-Plough succeeds
You may also be interested in...
Merck agrees to pay a maximum of $10 million to consumers to settle class-action case and to comply with labeling and claims regulations that will become law in December for most firms under an FDA final rule. The settlement in federal court resolves separate litigation against Coppertone filed in California state court.